Research & Literature

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.

Schalk G, Kirschfink M, Wehling C, et al.

Pediatric nephrology (Berlin, Germany) 2015; (30(6)):1039-42 doi:10.1007/s00467-015-3078-6.

Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome.

Cullinan N, Gorman KM, Riordan M, et al.

Pediatrics 2015; (135(6)):e1506-9 doi:10.1542/peds.2014-3503.

A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.

Yoshida Y, Miyata T, Matsumoto M, et al.

PloS one 2015; (10(5)):e0124655 doi:10.1371/journal.pone.0124655.

METAMORPHOPSIA AND ITS QUANTIFICATION.

Simunovic MP

Retina (Philadelphia, Pa.) 2015; (35(7)):1285-91 doi:10.1097/IAE.0000000000000581.

Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome.

Szarvas N, Szilágyi Á, Csuka D, et al.

Molecular immunology 2016; (71()):10-22 doi:10.1016/j.molimm.2016.01.003.

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.

Greenbaum LA, Fila M, Ardissino G, et al.

Kidney international 2016; (89(3)):701-11.

Retinal disease in the C3 glomerulopathies and the risk of impaired vision.

Savige J, Amos L, Ierino F, et al.

Ophthalmic genetics 2016; (37(4)):369-376 doi:10.3109/13816810.2015.1101777.

Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.

Hyvärinen S, Meri S, Jokiranta TS

Blood 2016; (127(22)):2701-10 doi:10.1182/blood-2015-11-680009.

Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.

Jodele S, Dandoy CE, Danziger-Isakov L, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016; (22(7)):1337-1340 doi:10.1016/j.bbmt.2016.03.032.

Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury.

Laskowski J, Renner B, Le Quintrec M, et al.

Kidney international 2016; (90(1)):109-22.

Defining the genetics of thrombotic microangiopathies.

Vieira-Martins P, El Sissy C, Bordereau P, et al.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2016; (54(2)):212-9.

Anti-complement-factor H-associated glomerulopathies.

Durey MA, Sinha A, Togarsimalemath SK, Bagga A

Nature reviews. Nephrology 2016; (12(9)):563-78 doi:10.1038/nrneph.2016.99.

Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control.

Prohászka Z, Nilsson B, Frazer-Abel A, Kirschfink M

Immunobiology 2016; (221(11)):1247-58.

Atypical Hemolytic Uremic Syndrome Recurrence after Renal Transplantation: C3-Glomerulonephritis as an Initial Presentation.

Bouatou Y, Bacchi VF, Villard J, et al.

Transplantation direct 2015; (1(2)):e9 doi:10.1097/TXD.0000000000000518.

Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Fakhouri F, Fila M, Provôt F, et al.

Clinical journal of the American Society of Nephrology : CJASN 2017; (12(1)):50-59 doi:10.2215/CJN.06440616.

Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.

Laurence J, Haller H, Mannucci PM, et al.

Clinical advances in hematology & oncology : H&O 2016; (14 Suppl 11(11)):2-15.

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Goodship TH, Cook HT, Fakhouri F, et al.

Kidney international 2017; (91(3)):539-551 doi:10.1016/j.kint.2016.10.005.

Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern.

García Monteavaro C, Peralta Roselló C, Quiroga B, et al.

Case reports in nephrology 2016; (2016()):7471082 doi:10.1155/2016/7471082.

Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome.

Trojnár E, Józsi M, Uray K, et al.

Frontiers in immunology 2017; (8()):302 doi:10.3389/fimmu.2017.00302.

Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation.

Kerr H, Wong E, Makou E, et al.

The Journal of biological chemistry 2017; (292(32)):13345-13360 doi:10.1074/jbc.M117.795088.

Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.

Saha M, McDaniel JK, Zheng XL

Journal of thrombosis and haemostasis : JTH 2017; (15(10)):1889-1900 doi:10.1111/jth.13764.

High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.

McNamara LA, Topaz N, Wang X, et al.

MMWR. Morbidity and mortality weekly report 2017; (66(27)):734-737 doi:10.15585/mmwr.mm6627e1.

Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.

Brocklebank V, Johnson S, Sheerin TP, et al.

Kidney international 2017; (92(5)):1261-1271 doi:10.1016/j.kint.2017.04.028.

Complement factor H in AMD: Bridging genetic associations and pathobiology.

Toomey CB, Johnson LV, Bowes Rickman C

Progress in retinal and eye research 2018; (62()):38-57 doi:10.1016/j.preteyeres.2017.09.001.

Complete functional characterization of disease-associated genetic variants in the complement factor H gene.

Merinero HM, García SP, García-Fernández J, et al.

Kidney international 2018; (93(2)):470-481 doi:10.1016/j.kint.2017.07.015.

Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation.

Kim S, Park E, Min SI, et al.

Journal of Korean medical science 2018; (33(1)):e4 doi:10.3346/jkms.2018.33.e4.

Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R.

Cserhalmi M, Uzonyi B, Merle NS, et al.

Frontiers in immunology 2017; (8()):1800 doi:10.3389/fimmu.2017.01800.

C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.

Garg N, Zhang Y, Nicholson-Weller A, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018; (33(12)):2260-2265 doi:10.1093/ndt/gfx369.

Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.

Fox LC, Cohney SJ, Kausman JY, et al.

Nephrology (Carlton, Vic.) 2018; (23(6)):507-517 doi:10.1111/nep.13234.

C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction.

Bajwa R, DePalma JA, Khan T, et al.

Case reports in nephrology and dialysis 2018; (8(1)):25-34 doi:10.1159/000486848.

Standardized classification and reporting of glomerulonephritis.

Sethi S, Fervenza FC

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(2)):193-199 doi:10.1093/ndt/gfy220.

Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13.

Michael M, Turner N, Elenberg E, et al.

Clinical kidney journal 2018; (11(6)):791-796 doi:10.1093/ckj/sfy010.

Ravulizumab: First Global Approval.

McKeage K

Drugs 2019; (79(3)):347-352 doi:10.1007/s40265-019-01068-2.

Seizure as the Presenting Symptom for Atypical Hemolytic Uremic Syndrome.

Chan S, Weinstein AR

The Journal of emergency medicine 2019; (56(4)):441-443 doi:10.1016/j.jemermed.2018.12.034.

Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.

Valoti E, Alberti M, Iatropoulos P, et al.

Frontiers in immunology 2019; (10()):853 doi:10.3389/fimmu.2019.00853.

Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome.

Schönauer R, Seidel A, Grohmann M, et al.

Frontiers in genetics 2019; (10()):465 doi:10.3389/fgene.2019.00465.

Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database.

Puraswani M, Khandelwal P, Saini H, et al.

Frontiers in immunology 2019; (10()):1282 doi:10.3389/fimmu.2019.01282.

Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis.

Gonzalez Suarez ML, Thongprayoon C, Mao MA, et al.

Journal of clinical medicine 2019; (8(7)) doi:10.3390/jcm8070919.

Elevated surface-bound complement FH alters the function of platelets and monocytes in FHR1/3 null healthy individuals.

Bhasym A, Bhakuni T, Guchhait P

Blood cells, molecules & diseases 2019; (79()):102349 doi:10.1016/j.bcmd.2019.102349.

Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.

Zuber J, Frimat M, Caillard S, et al.

Journal of the American Society of Nephrology : JASN 2019; (30(12)):2449-2463 doi:10.1681/ASN.2019040331.

Clinicopathological features of C3 glomerulopathy in children: a single-center experience.

Drake KA, Ellington N, Gattineni J, et al.

Pediatric nephrology (Berlin, Germany) 2020; (35(1)):153-162 doi:10.1007/s00467-019-04388-3.

Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathy.

Campbell CM, Cassol C, Cataland SR, Kahwash R

European heart journal. Case reports 2020; (4(2)):1-6 doi:10.1093/ehjcr/ytaa050.

C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-/- Cfd-/- mice.

Zhang Y, Keenan A, Dai DF, et al.

JCI insight 2020; (5(9)).

Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring.

Iorember F, Nayak A

Pediatric nephrology (Berlin, Germany) 2021; (36(6)):1365-1375 doi:10.1007/s00467-020-04652-x.

Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.

Laurence J

Clinical advances in hematology & oncology : H&O 2020; (18(4)):221-230.

Long-term data on two sisters with C3GN due to an identical, homozygous CFH mutation and autoantibodies.

Hackl A, Erger F, Skerka C, et al.

Clinical nephrology 2020; (94(4)):197-206 doi:10.5414/CN110135.

Podocytes Produce and Secrete Functional Complement C3 and Complement Factor H.

Mühlig AK, Keir LS, Abt JC, et al.

Frontiers in immunology 2020; (11()):1833 doi:10.3389/fimmu.2020.01833.

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.

Tanaka K, Adams B, Aris AM, et al.

Pediatric nephrology (Berlin, Germany) 2021; (36(4)):889-898 doi:10.1007/s00467-020-04774-2.

The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.

Ariceta G, Dixon BP, Kim SH, et al.

Kidney international 2021; (100(1)):225-237 doi:10.1016/j.kint.2020.10.046.

Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

Mbaeyi SA, Bozio CH, Duffy J, et al.

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports 2020; (69(9)):1-41 doi:10.15585/mmwr.rr6909a1.

Functional Characterization of Rare Genetic Variants in the N-Terminus of Complement Factor H in aHUS, C3G, and AMD.

Wong EKS, Hallam TM, Brocklebank V, et al.

Frontiers in immunology 2020; (11()):602284 doi:10.3389/fimmu.2020.602284.

A Dimerization Site at SCR-17/18 in Factor H Clarifies a New Mechanism for Complement Regulatory Control.

Dunne OM, Gao X, Nan R, et al.

Frontiers in immunology 2020; (11()):601895 doi:10.3389/fimmu.2020.601895.

Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome.

Chaturvedi S, Dhaliwal N, Hussain S, et al.

Blood advances 2021; (5(5)):1504-1512 doi:10.1182/bloodadvances.2020003175.

Clinical and Genetic Characteristics of Atypical Hemolytic Uremic Syndrome in Children: A Chinese Cohort Study.

Wu D, Chen J, Ling C, et al.

Nephron 2021; (145(4)):415-427 doi:10.1159/000513009.

Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review.

McFarlane PA, Bitzan M, Broome C, et al.

Canadian journal of kidney health and disease 2021; (8()):20543581211008707 doi:10.1177/20543581211008707.

Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification.

Martín Merinero H, Zhang Y, Arjona E, et al.

Blood 2021; (138(22)):2185-2201 doi:10.1182/blood.2021012037.

Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration.

Lorés-Motta L, van Beek AE, Willems E, et al.

American journal of human genetics 2021; (108(8)):1367-1384 doi:10.1016/j.ajhg.2021.06.002.

De Novo and Recurrent Thrombotic Microangiopathy After Renal Transplantation: Current Concepts in Management.

Abbas F, Abbas SF

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2022; (20(6)):549-557 doi:10.6002/ect.2021.0069.

Clinicopathologic Implications of Complement Genetic Variants in Kidney Transplantation.

Ren Z, Perkins SJ, Love-Gregory L, et al.

Frontiers in medicine 2021; (8()):775280 doi:10.3389/fmed.2021.775280.

Systematic review of atypical hemolytic uremic syndrome biomarkers.

Raina R, Sethi SK, Dragon-Durey MA, et al.

Pediatric nephrology (Berlin, Germany) 2022; (37(7)):1479-1493 doi:10.1007/s00467-022-05451-2.

Unraveling Structural Rearrangements of the CFH Gene Cluster in Atypical Hemolytic Uremic Syndrome Patients Using Molecular Combing and Long-Fragment Targeted Sequencing.

Tschernoster N, Erger F, Walsh PR, et al.

The Journal of molecular diagnostics : JMD 2022; (24(6)):619-631 doi:10.1016/j.jmoldx.2022.02.006.

Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation.

Acosta-Medina AA, Moyer AM, Go RS, et al.

Blood advances 2023; (7(3)):340-350 doi:10.1182/bloodadvances.2021006416.

Clinical features of children with anti-CFH autoantibody-associated hemolytic uremic syndrome: a report of 8 cases.

Li Q, Kong X, Tian M, et al.

Renal failure 2022; (44(1)):1061-1069 doi:10.1080/0886022X.2022.2089167.

Phenotypic Expression of CFH Rare Variants in Age-Related Macular Degeneration Patients in the Coimbra Eye Study.

Farinha C, Barreto P, Coimbra R, et al.

Investigative ophthalmology & visual science 2022; (63(9)):5 doi:10.1167/iovs.63.9.5.

Atypical hemolytic uremic syndrome: Consensus of diagnosis and treatment in Taiwan.

Tseng MH, Lin SH, Tsai JD, et al.

Journal of the Formosan Medical Association = Taiwan yi zhi 2023; (122(5)):366-375 doi:10.1016/j.jfma.2022.10.006.

Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.

Cammett TJ, Garlo K, Millman EE, et al.

Molecular diagnosis & therapy 2023; (27(1)):61-74 doi:10.1007/s40291-022-00620-3.

An Evaluation of the Complement-Regulating Activities of Human Complement Factor H (FH) Variants Associated With Age-Related Macular Degeneration.

Biggs RM, Makou E, Lauder S, et al.

Investigative ophthalmology & visual science 2022; (63(12)):30 doi:10.1167/iovs.63.12.30.

Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome.

Khandelwal P, Joshi A, Mathur A, et al.

Pediatric nephrology (Berlin, Germany) 2023; (38(8)):2659-2668 doi:10.1007/s00467-022-05862-1.

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study.

Bouwmeester RN, Duineveld C, Wijnsma KL, et al.

Kidney international reports 2023; (8(1)):91-102 doi:10.1016/j.ekir.2022.10.013.

CFH-CFHR1 hybrid genes in two cases of atypical hemolytic uremic syndrome.

Sugawara Y, Kato H, Nagasaki M, et al.

Journal of human genetics 2023; (68(6)):427-430 doi:10.1038/s10038-023-01129-1.

Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation.

Duineveld C, Bouwmeester RN, Wijnsma KL, et al.

Kidney international reports 2023; (8(4)):715-726 doi:10.1016/j.ekir.2023.01.016.

Ischemic cerebrovascular complications with initial presentation of genetic atypical hemolytic uremic syndrome.

Sokola M, Toljan K, Almoushref A, et al.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2023; (32(8)):107238 doi:10.1016/j.jstrokecerebrovasdis.2023.107238.

Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies.

Lafayette RA, Charu V

Advances in therapy 2023; (40(12)):5557-5566 doi:10.1007/s12325-023-02654-3.

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP.

Kelen K, Horváth O, Kis É, et al.

International journal of molecular sciences 2023; (24(18)) doi:10.3390/ijms241814389.

Tips for Testing Adults With Suspected Genetic Kidney Disease.

Savige J

American journal of kidney diseases : the official journal of the National Kidney Foundation 2024; (83(6)):816-824 doi:10.1053/j.ajkd.2023.10.011.

[Comparative characteristics of the complement system in patients with C3-glomerulopathy and atypical hemolytic uremic syndrome of chronic course who suffered an acute episode of thrombotic microangiopathy].

Yurova VA, Kozlovskaya NL, Bobrova LA, et al.

Terapevticheskii arkhiv 2023; (95(6)):475-480 doi:10.26442/00403660.2023.06.202269.

Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange?

Ferri M, Zotta F, Donadelli R, et al.

Pediatric nephrology (Berlin, Germany) 2024; (39(11)):3263-3269 doi:10.1007/s00467-024-06373-x.

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.

Dixon BP, Kavanagh D, Aris ADM, et al.

Kidney medicine 2024; (6(8)):100855 doi:10.1016/j.xkme.2024.100855.

An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder.

Balaban DT, Levy M, Borrow R, Anderson MR

Expert opinion on biological therapy 2024; (24(11)):1193-1198 doi:10.1080/14712598.2024.2423002.

Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis.

Doshi K, Yusuf A, Licht C, et al.

Pediatric research 2025; (98(2)):491-497 doi:10.1038/s41390-024-03771-7.

Ulcerative Colitis Gone Rogue: A Case of Complement-Mediated Thrombotic Microangiopathy in Inflammatory Bowel Disease.

Yeboah EK, Thida AM, Moradi R, et al.

Cureus 2025; (17(2)):e78447 doi:10.7759/cureus.78447.

Simultaneous GA and CNV/MNV: incidence, characteristics, and treatments.

Kataoka K, Gale R, Li X, et al.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2025; (263(5)):1197-1212 doi:10.1007/s00417-024-06721-5.

Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report.

Yang H, Zhang J, Wu H, et al.

Frontiers in immunology 2025; (16()):1542973 doi:10.3389/fimmu.2025.1542973.

Complement-Mediated Kidney Disease and Living Donor Transplantation: Tailoring Approaches to Improve Outcomes.

Memon AA, Lentine KL, Caliskan Y

Current transplantation reports 2025; (12(1)) doi:10.1007/s40472-025-00466-8.

Thrombotic Microangiopathies.

Hanna R, Gibney R, Boysen-Osborn M

Emergency medicine clinics of North America 2025; (43(3)):407-420 doi:10.1016/j.emc.2025.03.008.

Evidence for the Pathogenicity of a CFH Variant in a Multigenerational Family with Cuticular Drusen.

Preiksaitiene E, Gurskytė V, Mikštienė V, et al.

Medicina (Kaunas, Lithuania) 2025; (61(9)) doi:10.3390/medicina61091649.

High risk and low incidence diseases: Meningococcal disease.

Cejin MC, Koyfman A, Long B

The American journal of emergency medicine 2026; (99()):114-122 doi:10.1016/j.ajem.2025.09.031.

[Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report].

Guo DD, Xiao YX, Wang WR, et al.

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(11)):1408-1413 doi:10.7499/j.issn.1008-8830.2503084.

Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS.

Afshar-Kharghan V

Hematology. American Society of Hematology. Education Program 2025; (2025(1)):147-153 doi:10.1182/hematology.2025000700C.

Targeting complement in atypical hemolytic and uremic syndrome: development and current status of eculizumab and ravulizumab

Maillard N, Provot F

Nephrologie & therapeutique 2026; (21(7)):587-595 doi:10.1684/ndt.2025.160.

Diagnosis and treatment of complement-mediated thrombotic microangiopathies: consensus of the Genetic Diseases Committee of the Chilean Society of Nephrology.

Musalem P, Bascur N, Sepúlveda RA, et al.

BMC nephrology 2026; (27(1)):21 doi:10.1186/s12882-025-04739-3.

Antimeningococcal Protection in Patients Receiving Terminal Complement Inhibitors.

Vujović A, Schaefer F, Sellier-Leclerc AL, et al.

Kidney international reports 2026; (11(2)):103700 doi:10.1016/j.ekir.2025.11.025.

Case Report: Possible C3 nephritic factor-driven complement-mediated severe hemolytic anemia and acute kidney injury in a child with Bordetella parapertussis infection.

Thorsen SU, Hansen AT, Hartling HJ, et al.

Frontiers in immunology 2025; (16()):1715464 doi:10.3389/fimmu.2025.1715464.

Salvaging sepsis-associated atypical hemolytic uremic syndrome with terminal complement blockade: A case report.

Qiu Y, Zhou S, Huang G, et al.

Medicine 2026; (105(4)):e47281 doi:10.1097/MD.0000000000047281.

Successful term pregnancy after renal transplant in end-stage renal disease with complement factor H-related mutation: A case report.

Balwani MR, Pasari A, Kashiv P, et al.

World journal of transplantation 2026; (16(1)):113117 doi:10.5500/wjt.v16.i1.113117.

From post-infectious glomerulonephritis to complement-mediated aHUS: a diagnostic challenge.

Alzabali S, AlRasheed R, Alanazi A, et al.

Pediatric nephrology (Berlin, Germany) 2026; (41(9)):2881-2883 doi:10.1007/s00467-026-07218-5.

Early recognition of atypical hemolytic uremic syndrome to prevent irreversible kidney injury: cardiac failure and refractory hypertension as critical clues in young patients.

Tsiamis N, Kole C, Stefanou E, et al.

CEN case reports 2026; (15(2)).

A systematic review of short-term outcomes in patients with anti-factor H associated atypical HUS managed with plasma exchanges versus eculizumab.

Sinha A, Bindal T, Zotta F, et al.

Pediatric nephrology (Berlin, Germany) 2026; (41(12)):4369-4378 doi:10.1007/s00467-026-07309-3.

A Narrative Review of C3 Glomerulopathy: From Pathogenesis to Targeted Therapy.

Jauhal A, Barr B, Girard L, et al.

Canadian journal of kidney health and disease 2026; (13()):20543581261442656 doi:10.1177/20543581261442656.

Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland.

Berthele A, Aktas O, Ayzenberg I, et al.

Therapeutic advances in neurological disorders 2026; (19()):17562864261442558 doi:10.1177/17562864261442558.

Breakthrough serogroup Y meningococcal disease in a vaccinated patient with myasthenia gravis receiving ravulizumab: a case report.

Strugar SŠ, Petrović P, Butić I, et al.

BMC infectious diseases 2026; (26(1)).

Infection risk mitigation with complement inhibitors in kidney disease.

Berghmans M, Seghers F, Mirioglu S, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2026; doi:10.1093/ndt/gfag113.

Geographic Atrophy in Patients with Age-Related Macular Degeneration Is Associated with Rare Variants in Complement Factor H and Complement Factor I.

de Breuk A, de Jong S, Bakker B, et al.

Ophthalmology science 2026; (6(6)):101171 doi:10.1016/j.xops.2026.101171.

Atypical Hemolytic Uremic Syndrome in Children and Adults With the Hot Spot C3 Gene Variant p.Arg161Trp.

Ter Steeg L, Bouwmeester RN, Ter Avest M, et al.

Kidney international reports 2026; (11(8)):106599 doi:10.1016/j.ekir.2026.106599.

A case report of atypical hemolytic uremic syndrome with a CFH mutation complicated by recurrent posterior reversible encephalopathy syndrome.

Maruyama R, Takeuchi D, Momose M, et al.

Medicine 2026; (105(27)):e49593 doi:10.1097/MD.0000000000049593.

Postpartum Atypical Hemolytic Uremic Syndrome Complicating β-Thalassemia Intermedia: A Case Report and Literature Review.

Gao B, Miao Y, Waseem S

Journal of clinical medicine 2026; (15(14)) doi:10.3390/jcm15145740.

Current practices in antibiotic prophylaxis for patients on complement inhibitors: a multicenter survey across ERN ERKnet centers.

Sciascia S, Terzolo E, Fenoglio R, et al.

Clinical kidney journal 2026; (19(9)):sfag282 doi:10.1093/ckj/sfag282.

Atypical hemolytic uremic syndrome in kidney transplantation.

Ponticelli C, Moroni G

Journal of nephrology 2026; (39(7)):1334-1341 doi:10.1093/joneph/aajag096.

Case Report: Fulminant meningococcus-meningitis under treatment with ravulizumab despite complete vaccination-a rare but severe complication.

Kozák G, Förster S, Haap M, et al.

Frontiers in medicine 2026; (13()):1943514 doi:10.3389/fmed.2026.1943514.

Excellent Response to Eculizumab in a Patient With Complement-Mediated Thrombotic Microangiopathy and a Novel Plasminogen Gene Variant.

Patel A, Powers B, Tsai J, Nukala S

Case reports in hematology 2026; (2026()):1318626 doi:10.1155/crh/1318626.

Laboratory Diagnosis of Complement-Mediated Diseases: A Practical Overview.

Valentini A, Bernardini S

The journal of applied laboratory medicine 2026; doi:10.1093/jalm/jfag158.

Thrombotic microangiopathy after kidney transplant: a mechanistic + therapeutic decision tree.

Chutani A, Francis JM, Mahmoud H

Current opinion in nephrology and hypertension 2026; doi:10.1097/MNH.0000000000001239.